Getting a Second Opinion

Doctors aren’t perfect. But we non-doctors often act like they are perfect, or at least infallible when it comes to diagnosing and treating us. It’s madness, if you think about it—trusting one person to make potentially life-determining decisions about us.



It’s bad enough we bring our cars to mechanics and take their word for all their charges. We should never be as lackadaisical about our health and happiness, especially when the diagnosis is lymphoma.



That’s where a second opinion comes in. But we wince at the thought, don’t we? We don’t want to offend our first doctor by second-guessing him or her, but this is serious: this is cancer. To hell with hurting that doctor’s feelings. Getting a second opinion is an absolutely crucial step in your wider treatment plan.



The Leukemia & Lymphoma Society has a wonderfully informative section on seeking second opinions. Click here for printable questions to ask during your second opinion consultation (from the LLS), and click here for questions to ask your health insurer regarding getting a second opinion consultation.



If each doctor tells you something differently, you may need a third opinion. Whatever the case, get all the opinions you can get or need--now is not the time to be courteous or timid.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap